Application Of Ct-Guided Ad-P53 Intratumoral Injection For Recurrent And Metastatic Gynecologic Cancer Patients Who Received Chemoradiation Therapy

Fan Shi,Tao Wang,Jiquan Wang,Jin Su,Yunyi Yang,Yingbing Zhang,Yanlan Chai,E.K. Drokow,Zi Liu

DOI: https://doi.org/10.1016/j.ijrobp.2016.06.1391

2016-01-01

Abstract:Observing the safety and effectiveness of CT-guide Ad-P53 intratumoral injection to treat patient with recurrent and metastatic gynecologic cancer who underwent local radiation therapy and veinal chemotherapy without other treatment. From October 2012 to December 2015, the Gynecological Radiation Oncology Division, of the First Affiliated Hospital of Xi’an Jiaotong University treated 122 patients with recurrent and metastatic pelvic tumor, of which 47 received local radiation therapy and veinal chemotherapy before having CT-guide Ad-P53 therapy with local multi-point injection into tumor. In each injection, one (1012VP, viral particles) to four medicines was used and diluted to 4-16ml with normal saline; administrated once per week, for 1-6 times altogether. Forty-seven patients received treatment 91 times in total, with dosage of 2±1 pieces on average. The treatment was performed with no radiation therapy and chemotherapy, and considered to end when the tumor regressed or the patient could not tolerate other treatment. Therapeutic evaluation: (1) objective therapeutic evaluation: The efficacy was evaluated one month after treatment according to WHO (Response Evaluation Criteria in Solid Tumors), in combination with the maximum sectional area of the tumor measured through pelvis MRI scan and the regression rate (%) obtained. The safety of implant needle by the CT scan was also observed. (2) Subjective therapeutic evaluation: It was based on the extent of pain relief and vaginal discharge of the patient. 47 patients were follow-up to 27 months and median follow-up time of 11 months by February 2016. Their generation material listed Table 1. No patient had blood vessels, colorectal, bladder and ureter injury resulting from injection medicines by CT-guide. Forty patients (85.1%) had high fever (≥38.5°C) transitorily. Therapeutic evaluation both subjective and objective was made one month after treatment. The results showed that pain and vaginal discharge achieved notable remission of 41 patients (87.2%) and 22 patients (22/27, 81.5%), respectively. 37 patients (78.7%) had appetite and sleeping improved. The objective clinical benefit ratio (CR+PR+SD> one month) of 80.9% (38/47), see Table 2. The median survival time of 11.6 months; 40 ( 85.1%) patients experienced worsen conditions with median progression-free survival of five months. 4 patients whose appetite and sleeping quality were improved after treatment received palliative chemotherapy again. 22 patients (46.8%) died. CT-guide Ad-P53 local injection therapy helps recurrent and metastatic gynecological patients to have effective pain relief, improve quality of life, and showed high safety level. The use of virus vector comes with certain side effect such high fever while the disease remission was shorter. Hence further clinical study and vital fundamental researches are needed on how to conduct gene therapy in a safe and effective way.